(MENAFN- EIN Presswire) EINPresswire/ -- What Is The Expected Cagr For The Enzyme Replacement Therapy Market Through 2025?
The market size of enzyme replacement therapy has encountered significant expansion in the last few years. It is projected to increase from $11.58 billion in 2024 to $12.36 billion in 2025, indicating a compound annual growth rate (CAGR) of 6.7%. This growth during the historical timeframe can be credited to factors like early therapeutic revelations, advancement in treatment approvals, a broader comprehension of diseases, clinical triumphs, as well as supportive regulations and incentives.

Expectations are high for significant expansion in the enzyme replacement therapy market in the coming years. The market is projected to reach a value of ""$17.48 billion in 2029, growing at a compound annual growth rate (CAGR) of 9.0%. The predicted growth throughout the forecast period can be linked to factors such as increased patient healthcare accessibility, personalized therapies and medicine, amendments in regulatory framework, and heightened patient population awareness. Key trends projected for the forecast period encompass the integration of digital health technology, an emphasis on patient-focused solutions, the rise in biomarker research, and the approach of precision medicine.

Download a free sample of the enzyme replacement therapy market report:

What Are The Driving Factors Impacting The Enzyme Replacement Therapy Market?
The enzyme replacement therapy market is anticipated to witness an upward trend primarily due to the escalating incidences of unique, chronic, and genetic diseases. A chronic disease is categorized as any ailment that extends for a period of three months or longer, with a tendency to worsen over time. Generally, such diseases are prevalent in the aged population and can predominantly be managed but not completely cured. An exemplar of this is the statistical data released by the American Lung Association, a non-profit organization based in the US, in July 2024. It revealed that in 2022, health professionals diagnosed asthma in 44.2 million Americans - accounting for 13.5% of the population - marking an increase from 12.9% in the previous year. This rising incidence rate of unique, chronic, and inherited diseases is bound to stimulate the growth of the enzyme replacement therapy market.

Which Players Dominate The Enzyme Replacement Therapy Industry Landscape?
Major players in the Enzyme Replacement Therapy include:
. Biomarin Pharmaceutical Inc.
. Leadiant Biosciences Inc.
. Pfizer Inc.
. Sanofi S.A.
. AbbVie Inc.
. Johnson & Johnson Services Inc.
. Alexion Pharmaceuticals Inc.
. Recordati Rare Diseases Inc.
. Sangamo Therapeutics Inc.
. JCR Pharmaceuticals Co. Ltd.

What Are The Future Trends Of The Enzyme Replacement Therapy Market?
Gaining traction in the enzyme replacement therapy market is the key trend of product approvals. Several medications relating to this therapy proposed by key industry players are receiving validation in the marketplace. For example, in February 2023, Lamzede (velmanase alfa) became the country's first enzyme-replacement therapeutic drug approved by the Food and Drug Administration (FDA), a national agency in the United States that falls under the Department of Health. This novel treatment is specifically for non-central neurological indications of a rare genetic disorder known as alpha-mannosidosis, marked by the lack of alpha-mannosidase enzyme within the human body. Lamzede aids patients in resuming normal cellular operation by functioning similarly to the alpha-mannosidase enzyme, serving to reinstate healthy cellular activity. The patients receive Lamzede through a weekly 10mg injection.

Global Enzyme Replacement Therapy Market Segmentation By Type, Application, And Region
The enzyme replacement therapy market covered in this report is segmented –

1) By Enzyme Type: Agalsidase Alfa, Agalsidase Beta, Galsulfase, Other Enzyme Types
2) By Route Of Administration: Oral, Parenteral
3) By Application: Gaucher Disease, Pompe Disease, Fabry Disease, Other Applications
4) By End-Users: Hospitals, Infusion Centers, Other End-Users

Subsegments:
1) By Agalsidase Alfa: Fabry Disease Treatment
2) By Agalsidase Beta: Fabry Disease Treatment
3) By Galsulfase: Mucopolysaccharidosis VI (MPS VI) Treatment
4) By Other Enzyme Types: Alglucosidase Alfa, Idursulfase, Velaglucerase Alfa

View the full enzyme replacement therapy market report:

Which Region Holds The Largest Market Share In The Enzyme Replacement Therapy Market?
In 2024, North America dominated the enzyme replacement therapy market while Asia-Pacific is predicted to experience the most rapid growth during the forecast period. The report on the enzyme replacement therapy market comprises of regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Reports Similar to the Global Enzyme Replacement Therapy Market 2025, By The Business Research Company

Hydrolase Enzymes Global Market Report 2025
/report/hydrolase-enzymes-global-market-report

Protein Hydrolysis Enzymes Global Market Report 2025
/report/protein-hydrolysis-enzymes-global-market-report

Fruit And Vegetable Processing Enzymes Global Market Report 2025
/report/fruit-and-vegetable-processing-enzymes-global-market-report

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email:...
The Business Research Company -

Follow Us On:
. LinkedIn:

MENAFN24112025003118003196ID1110387765